Trial Profile
A Phase IV double blind placebo controlled cross-over study on the effects of Fampyridine on low contrast visual acuity in patients with previous demyelinating optic neuritis.
Status:
Discontinued
Phase of Trial:
Phase IV
Latest Information Update: 09 Dec 2019
Price :
$35
*
At a glance
- Drugs Fampridine (Primary)
- Indications Multiple sclerosis; Optic neuritis
- Focus Therapeutic Use
- 04 Dec 2019 Status changed from not yet recruiting to discontinued.
- 28 Jul 2014 New trial record